• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[重组组织型纤溶酶原激活剂(rt-PA)用于骨髓移植后希克曼导管闭塞性血栓形成:临床及凝血生理学方面]

[Use of recombinant tissue plasminogen activator (rt-PA) in occluding thrombosis of a Hickman catheter after bone marrow transplantation: clinical and coagulation physiologic aspects].

作者信息

Eckhof-Donovan S, Michelmann I, Nürnberger W, Stieh J, Rost B, Kemperdick H, Göbel U

机构信息

Klinik für pädiatrische Hämatologie und Onkologie, Heinrich Heine Universität, Düsseldorf, FRG.

出版信息

Klin Padiatr. 1993 Nov-Dec;205(6):435-9. doi: 10.1055/s-2007-1025265.

DOI:10.1055/s-2007-1025265
PMID:8309209
Abstract

A 12 year-old female patient suffering from multifocal Ewing's Sarcoma underwent bone marrow transplantation in March 1992. The donor was the patient's HLA-identical brother. On day 38 following BMT, an occluding catheter thrombosis of the superior vena cava was diagnosed. Lysis therapy using rt-PA was initiated. During therapy, serious bleeding occurred and administration was temporarily discontinued. Normalisation of previously high fibrinogen levels during an acute phase reaction was seen concomitantly with systemic fibrin and probably also fibrinogen fragments as demonstrated using the Western blot technique. Lysis therapy resulted in regained catheter patency, while thrombosis of the superior vena cava persisted. The reduction in the need for the transfusion of packed thrombocytes following lysis was seen as being a positive result. The use of rt-PA following BMT should be carefully weighed against the risks and requires careful patient observation. Due to the systemic fibrinolytic and fibrinogenolytic effects combined with mucositis and thrombocytopenia as a result of transplantation therapy, a high risk of bleeding complications seems likely.

摘要

一名患有多灶性尤因肉瘤的12岁女性患者于1992年3月接受了骨髓移植。供体是该患者HLA匹配的兄弟。骨髓移植后第38天,诊断出上腔静脉闭塞性导管血栓形成。开始使用rt-PA进行溶栓治疗。治疗期间,发生了严重出血,给药暂时中断。急性期反应期间先前升高的纤维蛋白原水平恢复正常,同时出现全身性纤维蛋白,可能还有纤维蛋白原片段,这通过蛋白质免疫印迹技术得到证实。溶栓治疗使导管恢复通畅,但上腔静脉血栓仍然存在。溶栓后浓缩血小板输注需求的减少被视为一个积极结果。骨髓移植后使用rt-PA应仔细权衡风险,并且需要对患者进行仔细观察。由于移植治疗导致的全身性纤维蛋白溶解和纤维蛋白原溶解作用,再加上粘膜炎和血小板减少症,出血并发症的风险似乎很高。

相似文献

1
[Use of recombinant tissue plasminogen activator (rt-PA) in occluding thrombosis of a Hickman catheter after bone marrow transplantation: clinical and coagulation physiologic aspects].[重组组织型纤溶酶原激活剂(rt-PA)用于骨髓移植后希克曼导管闭塞性血栓形成:临床及凝血生理学方面]
Klin Padiatr. 1993 Nov-Dec;205(6):435-9. doi: 10.1055/s-2007-1025265.
2
[Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator].
Klin Padiatr. 1991 Sep-Oct;203(5):363-5. doi: 10.1055/s-2007-1025454.
3
Use of tissue plasminogen activator for thrombolysis in occluded peritoneal dialysis catheters in children.组织纤溶酶原激活剂用于儿童闭塞性腹膜透析导管溶栓治疗。
Adv Perit Dial. 2001;17:249-52.
4
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).大剂量组织型纤溶酶原激活剂及血浆半衰期延长的杂交纤溶酶原激活剂(K2tu-PA:CGP 42935)的溶栓和出血作用
Thromb Haemost. 1993 Aug 2;70(2):294-300.
5
Treatment of superior vena cava syndrome with recombinant tissue plasminogen activator in a sickle cell patient undergoing bone marrow transplantation.重组组织型纤溶酶原激活剂治疗镰状细胞病患者骨髓移植期间的上腔静脉综合征
Pediatr Hematol Oncol. 2001 Jan-Feb;18(1):71-7. doi: 10.1080/088800101750059882.
6
In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.体外凝块溶解作为血栓对纤维蛋白溶解抵抗的潜在指标——在健康受试者中的研究及其与血液纤溶参数的相关性
Thromb Haemost. 1997 Apr;77(4):725-9.
7
Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.在犬动静脉联合血栓形成模型中组织型纤溶酶原激活剂与纤溶酶原激活剂抑制剂-1抗性糖基化变体的溶栓特性比较
Thromb Haemost. 1994 Jul;72(1):98-104.
8
Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator.采用重组组织型纤溶酶原激活剂持续静脉输注对深静脉血栓形成进行溶栓治疗。
Semin Thromb Hemost. 1991 Jan;17(1):48-54. doi: 10.1055/s-2007-1002589.
9
[Thrombolytic therapy of deep venous thrombosis with rt-PA].
Klin Wochenschr. 1988;66 Suppl 12:137-42.
10
Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
Thromb Haemost. 1996 May;75(5):816-9.